| Year |
Citation |
Score |
| 2018 |
Yao Z, Wardell S, Spasojevic I, Norris J, Katzenellenbogen J, McDonnell D, Josan JS. Abstract 1805: Development of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer Cancer Research. 78: 1805-1805. DOI: 10.1158/1538-7445.Am2018-1805 |
0.377 |
|
| 2017 |
Rodríguez-Corrales JÁ, Josan JS. Resazurin Live Cell Assay: Setup and Fine-Tuning for Reliable Cytotoxicity Results. Methods in Molecular Biology (Clifton, N.J.). 1647: 207-219. PMID 28809005 DOI: 10.1007/978-1-4939-7201-2_14 |
0.309 |
|
| 2017 |
Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Hormones & Cancer. PMID 28194662 DOI: 10.1007/S12672-017-0285-6 |
0.371 |
|
| 2017 |
Josan J, Pokludova K, Devi S, Srinivasan S, Katzenellenbogen J, Nettles K. Abstract P2-08-07: Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-08-07 |
0.3 |
|
| 2016 |
Nwachukwu JC, Srinivasan S, Zheng Y, Wang S, Min J, Dong C, Liao Z, Nowak J, Wright NJ, Houtman R, Carlson KE, Josan JS, Elemento O, Katzenellenbogen JA, Zhou HB, et al. Predictive features of ligand-specific signaling through the estrogen receptor. Molecular Systems Biology. 12: 864. PMID 27107013 DOI: 10.15252/Msb.20156701 |
0.579 |
|
| 2016 |
Nwachukwu JC, Srinivasan S, Zheng Y, Wang S, Min J, Dong C, Liao Z, Nowak J, Wright NJ, Houtman R, Carlson KE, Josan JS, Elemento O, Katzenellenbogen JA, Zhou HB, et al. Predictive features of ligand-specific signaling through the estrogen receptor Molecular Systems Biology. 12. DOI: 10.15252/msb.20156701 |
0.512 |
|
| 2015 |
Huynh AS, Estrella V, Stark VE, Cohen AS, Chen T, Casagni TJ, Josan JS, Lloyd MC, Johnson J, Kim J, Hruby VJ, Vagner J, Morse DL. Tumor Targeting and Pharmacokinetics of a Near Infrared Fluorescent-labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Molecular Pharmaceutics. PMID 26713599 DOI: 10.1021/Acs.Molpharmaceut.5B00760 |
0.488 |
|
| 2012 |
Xu L, Josan JS, Vagner J, Caplan MR, Hruby VJ, Mash EA, Lynch RM, Morse DL, Gillies RJ. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proceedings of the National Academy of Sciences of the United States of America. 109: 21295-300. PMID 23236171 DOI: 10.1073/Pnas.1211762109 |
0.623 |
|
| 2011 |
Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, Gillies RJ, Morse DL, Vagner J. Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. Journal of Medicinal Chemistry. 54: 8078-84. PMID 22011200 DOI: 10.1021/Jm201226W |
0.657 |
|
| 2011 |
Josan JS, Handl HL, Sankaranarayanan R, Xu L, Lynch RM, Vagner J, Mash EA, Hruby VJ, Gillies RJ. Cell-specific targeting by heterobivalent ligands. Bioconjugate Chemistry. 22: 1270-8. PMID 21639139 DOI: 10.1021/Bc1004284 |
0.746 |
|
| 2011 |
Josan JS, De Silva CR, Yoo B, Lynch RM, Pagel MD, Vagner J, Hruby VJ. Fluorescent and lanthanide labeling for ligand screens, assays, and imaging. Methods in Molecular Biology (Clifton, N.J.). 716: 89-126. PMID 21318902 DOI: 10.1007/978-1-61779-012-6_6 |
0.561 |
|
| 2009 |
Xu L, Vagner J, Josan J, Lynch RM, Morse DL, Baggett B, Han H, Mash EA, Hruby VJ, Gillies RJ. Enhanced targeting with heterobivalent ligands. Molecular Cancer Therapeutics. 8: 2356-65. PMID 19671749 DOI: 10.1158/1535-7163.Mct-08-1183 |
0.719 |
|
| 2009 |
Josan JS, Morse DL, Xu L, Trissal M, Baggett B, Davis P, Vagner J, Gillies RJ, Hruby VJ. Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Organic Letters. 11: 2479-82. PMID 19445485 DOI: 10.1021/Ol900200K |
0.591 |
|
| 2009 |
Fernandes SM, Sankaranarayanan R, Xu L, Josan J, Vagner J, Gillies R, Hruby VJ. Synthesis of bivalent MSH ligands and evaluation of their binding to hMC4R using MSH lanthaligand. Advances in Experimental Medicine and Biology. 611: 433-4. PMID 19400253 DOI: 10.1007/978-0-387-73657-0_186 |
0.677 |
|
| 2009 |
Josan JS, Sankaranarayanan R, Handl HL, Fernandes S, Xu L, Vagner J, Gillies RJ, Hruby VJ. Heterobivalent ligands crosslink multiple cell-surface receptors--a step towards personal medicine. Advances in Experimental Medicine and Biology. 611: 413-4. PMID 19400245 DOI: 10.1007/978-0-387-73657-0_178 |
0.716 |
|
| 2008 |
Josan JS, Vagner J, Handl HL, Sankaranarayanan R, Gillies RJ, Hruby VJ. Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors. International Journal of Peptide Research and Therapeutics. 14: 293-300. PMID 19714261 DOI: 10.1007/S10989-008-9150-3 |
0.738 |
|
| 2008 |
Vagner J, Xu L, Handl HL, Josan JS, Morse DL, Mash EA, Gillies RJ, Hruby VJ. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angewandte Chemie (International Ed. in English). 47: 1685-8. PMID 18205159 DOI: 10.1002/Anie.200702770 |
0.666 |
|
| 2007 |
Handl HL, Sankaranarayanan R, Josan JS, Vagner J, Mash EA, Gillies RJ, Hruby VJ. Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjugate Chemistry. 18: 1101-9. PMID 17591746 DOI: 10.1021/Bc0603642 |
0.731 |
|
| 2007 |
Josan JS, Vagner J, Xu L, Morse DL, Gillies RJ, Hruby VJ. CMR 2007: 4.02: A novel targeting approach to molecular imaging based on heteromultivalency Contrast Media & Molecular Imaging. 2: 283-283. DOI: 10.1002/Cmmi.174 |
0.448 |
|
| 2006 |
Kaur N, Monga V, Josan JS, Lu X, Gershengorn MC, Jain R. Synthesis, receptor binding, and activation studies of N(1)-alkyl-L-histidine containing thyrotropin-releasing hormone (TRH) analogues. Bioorganic & Medicinal Chemistry. 14: 5981-8. PMID 16735122 DOI: 10.1016/J.Bmc.2006.05.031 |
0.325 |
|
| Show low-probability matches. |